Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Relative Bioavailability of BI 691751 With and Without Food
NCT02175238Phase 1Withdrawn
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of BI 691751 in atherosclerosis (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Area under the concentration-time curve of the analyte in plasma and whole blood over the time interval from 0 to the last quantifiable data point up to 480 hours and Maximum measured concentration of the analyte in plasma and whole blood up to 480 hours. Planned start Jul 2014; status: withdrawn.
02
Drugs
BI 691751
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT02175238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02175238.